Nexeon Medsystems (OTCMKTS: NXNND) is one of 47 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Nexeon Medsystems to similar businesses based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, earnings and profitability.
This is a breakdown of current ratings and recommmendations for Nexeon Medsystems and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nexeon Medsystems Competitors||187||547||1118||46||2.54|
Earnings and Valuation
This table compares Nexeon Medsystems and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nexeon Medsystems Competitors||$1.25 billion||$101.33 million||-18.73|
Nexeon Medsystems’ rivals have higher revenue and earnings than Nexeon Medsystems.
This table compares Nexeon Medsystems and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nexeon Medsystems Competitors||-129.98%||-102.32%||-25.44%|
Insider & Institutional Ownership
42.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 61.2% of Nexeon Medsystems shares are held by insiders. Comparatively, 15.4% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nexeon Medsystems beats its rivals on 4 of the 7 factors compared.
About Nexeon Medsystems
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with MarketBeat.com's FREE daily email newsletter.